Busadre, Joy D.

HRN: 01-18-25  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/03/2023
CLINDAMYCIN 300MG (CAP)
12/03/2023
12/10/2023
PO
300mg
TID
Invasive Breat Ca, Left, Infected
Waiting Final Action 

Indication:  Empirical De-escalation    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: